Truist analyst Nicole Germino lowered the firm’s price target on Sangamo (SGMO) to $5 from $7 and keeps a Buy rating on the shares. The firm is updating its model to reflect the return of a BLA-ready Phase 3 asset with competitive data in Hem A and pending more clarity on the longer-term cash position from a potentially near-term announcement of a partner for Phase 3 Fabry disease asset and additional capsid partnerships, the analyst tells investors in a research note. Truist adds that the longer-term cash runway for Sangamo hinges on a partner for Fabry, which may come with a meaningful upfront and royalties payments, removing the cash overhang.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMO:
- Biotech Alert: Searches spiking for these stocks today
- Top 3 Trending Stocks, According to Analysts – 1/2/2025
- 3 Best Stocks to Buy Now, 1/1/2025, According to Top Analysts
- CompoSecure to spin off Resolute, EHang raises Q4 revenue view; Morning Buzz
- Sangamo selloff on Pfizer decision overdone, says H.C. Wainwright